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Abstract: Infection with Shiga toxin-producing Escherichia coli (STEC) may cause hemorrhagic 
colitis, hemolytic uremic syndrome (HUS) and encephalopathy. The mortality rate derived from 
HUS adds up to 5% of the cases, and up to 40% when the central nervous system (CNS) is in-
volved. In addition to the well-known deleterious effect of Stx, the gram-negative STEC releases 
lipopolysaccharides (LPS) and may induce a variety of inflammatory responses when released in 
the gut. Common clinical signs of severe CNS injury include sensorimotor, cognitive, emotional 
and/or autonomic alterations. In the last few years, a number of drugs have been experimentally 
employed to establish the pathogenesis of, prevent or treat CNS injury by STEC. The strategies in 
these approaches focus on: 1) inhibition of Stx production and release by STEC, 2) inhibition of Stx 
bloodstream transport, 3) inhibition of Stx entry into the CNS parenchyma, 4) blockade of deleteri-
ous Stx action in neural cells, and 5) inhibition of immune system activation and CNS inflamma-
tion. Fast diagnosis of STEC infection, as well as the establishment of early CNS biomarkers of 
damage, may be determinants of adequate neuropharmacological treatment in time. 
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1. INTRODUCTION 
 Shiga-like toxins (Stx), also known as verotoxins [1], are 
a virulence factor released by enterohemorrhagic E. coli 
(EHEC) and non-EHEC bacteria, both generically called 
Shiga-toxin-producing E. coli (STEC) [2, 3]. 
 Shiga toxins belong to an AB family of bacterial toxins, 
which includes tetanus (from Clostridium tetani), cholera 
(from Vibrio cholerae), anthrax (from Bacillus anthracis) 
and diphtheria toxins (from Corynebacterium diphtheriae), 
among others [4]. AB toxins are named after their two basic 
protein components: the catalytic A component exerts its 
action in intracellular molecules, while the B component is 
responsible for the binding of the toxin to specific receptors 
on target cells [4, 5]. In the case of Stx (Fig. 1), the B subunit 
is a homopentamer-structure that recognizes the receptor 
globotriaosylceramide (Gb3). 
 The interaction between Stx and Gb3 is responsible for 
the hemolytic-uremic syndrome (HUS), a clinical syndrome 
which primarily targets children up to 5 years of age [6]. HUS  
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is a triad characterized by thrombocytopenia, microangiopathic 
hemolytic anemia and variable degrees of renal compromise, 
ranging from minor urine abnormalities to severe renal dis-
ease, which may be preceded by prodromal bloody diarrhea 
in STEC-infected patients [6-11]. STEC causes more than 
2.8 million annual acute illnesses worldwide, leading to 3890 
cases of HUS and 230 deaths [12]. The central nervous sys-
tem (CNS) is frequently affected, producing an acute en-
cephalopathy which is responsible for a worse prognosis. 
The mortality rate derived from HUS adds up to 5% of the 
cases, and up to 40% when the CNS is involved [13]. 
 Stx genes are encoded within a chromosomally integrated 
lambdoid prophage genome [14-16]. Antibiotics promote 
Shiga toxin production by inducing the lithic cycle of the 
lambda bacteriophage, thus enhancing the replication and 
expression of Stx genes. For these reasons, the use of con-
ventional antibiotics is contraindicated and even increases 
the risk of developing HUS [17]. At present, there is no 
consensus high-efficiency treatment for STEC infections 
[18]. In addition to Stx, STEC also releases lipopolysaccha-
rides (LPS), the main component of the outer membrane of 
Gram-negative bacteria responsible for serogroup identifica-
tion (O antigen) [5]. The frequent endotoxemia observed in 
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 STEC major reservoir is cattle; therefore, human infec-
tion is produced through the consumption of contaminated 
bovine-derived products, contaminated water, unpasteurized 
apple drinks and vegetables. STEC has a low infective dose; 
only 10 colony-forming units can produce an infection in 
humans, which allows potential direct transmission through 
contact with infected people or animals [20-23]. 
2. STX MECHANISM OF ACTION 
 Based on their serological neutralization profile, there are 
two main groups of Stx: Stx1, which has a molecular mass of 
70 kDa, and Stx2, which has 60 kDa [24]. Each group, in 
turn, comprises various subtypes named in letters [25]. Stx1 
shows remarkable homology with Stx from Shigella dysente-
riae. Furthermore, it can be neutralized by antibodies raised 
against Stx, as they differ in only one amino acid residue. On 
the other hand, Stx2 shows around 55 % homology with 
Shigella´s toxin and cannot be neutralized by Shigella-raised 
antibodies [26]. Although the affinity of Stx1 to its receptor 
is 10-fold higher than that of Stx2, the latter has 400-fold 
higher toxicity than Stx1 in mice [27] and is primarily re-
sponsible for severe cases in human infections [28-31]. 
 The B subunit of Stx is a homopentameric protein non-
covalently associated with the A subunit by its terminal car-
boxyl extreme [4, 32]. The B homopentamer binds to the 
membrane receptor globotriaosylceramide (Gb3), a gly-
cosphingolipid present on a detergent-insoluble portion of 
lipid raft membranes rich in cholesterol [33]. 
 Once the interaction of StxB-Gb3 occurs, it evokes an 
endocytic process which may be clathrin-dependent or inde-
pendent [34, 35] and which culminates in a retrograde path-
way that ends in the cytosol. Early endosomes containing Stx 
escape the lysosomal pathway to the trans-Golgi network 
and the Golgi apparatus to finally reach the endoplasmic 
reticulum. The A subunit contains a loop formed by a disul-
fide bond involving two cysteines in positions 242 and 261. 
This loop area contains the sequence Arg-X-X-Arg, which is 
enzymatically cleaved by furin in two different chains: A1, 
which has a molecular mass of 27.5kDa, and A2, with a mo-
lecular mass of A2 4.5 kDa [33, 36]. These two chains re-
main linked by a disulfide bond. The A1 chain –which con-
tains the catalytic N-glycosidase activity–subsequently trans-
locates to the cell cytosol and removes the adenine residue 
2260 of 28S eukaryotic rRNA. Thus, protein synthesis is 
inhibited at the translational level as the elongation factor 
EIF2a no longer binds to ribosomes [37-39], which triggers a 
ribotoxic stress response of pro-apoptotic and pro-
inflammatory events [27, 40] (Fig. 1). 
 Gb3 is heterogeneously distributed in the body. It may be 
found in endothelial cells, hematopoietic cells, pancreas, 
heart, liver, kidney and the CNS [8]. Although the Gb3 bio-
logical function has not been entirely elucidated yet, recent 
evidence suggests that it plays an essential role in protein 
reabsorption by renal proximal tubules [41]. Furthermore, 
Gb3 is the Pk antigen from the human P blood group system 
[42, 43] and the CD77 antigen associated to Burkitt’s lym-
phoma [44]; it is also present in activated B-cells which un-
dergo apoptosis after not being selected for plasma ce11 dif-
ferentiation in germinal centers of lymphoid tissue [45]. 
 Gb3 consists of a ceramide moiety composed of different 
fatty acid chains linked by an amide bond to a sphingosine, 
which, in turn, is linked to a sugar chain (galactose α 1-4 
galactose β 1-4 glucose). The ceramide element is composed 
by relatively constant sphingosine and a highly variable fatty 
acid chain which, depending on the cell type and the stage of 
the cell cycle, may show different lengths and degrees of 
saturation [46]. Therefore, there are many Gb3 isoforms 
whose fatty acid chain length and saturation degree influence 
the cytotoxic action of Stx, with long fatty acid chains being 
responsible for greater toxicity. The amount of cholesterol 
 
Fig. (1). Crystal structure of Shiga toxin. A: crystal structure of Shiga toxin. The A-subunit is shown in dark blue and the B-subunit is 
shown in different colors (PDB #1R4P); B: Shiga toxin B-subunit with individual B-monomers is shown in different colors (PDB #3MXG); 
PDB images were obtained from Research Collaboratory for Structural Bioinformatics Protein Data Base (www.rcsb.org). (A higher resolu-
tion / colour version of this figure is available in the electronic copy of the article). 
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and phosphatidylcholine seems to be an important factor 
responsible for toxin internalization [4, 47, 48]. It has been 
reported that cholesterol microdomains enhance the binding 
and the entry of Stx [4], probably because cholesterol can 
modulate the orientation of the carbohydrate group of Gb3 
[48]. 
 Polymorphonuclear leukocytes (PMN), which do not 
express Gb3, have been reported to be the main carriers of 
Stx from the intestine to systemic organs [49-53]. Stx binds 
to PMN via the TLR4 receptor, which has a 100-fold lower 
affinity than the Gb3 receptor; however, pre-treatment with 
LPS induces a 30-fold increase in specific binding sites for 
Stx on PMN [54]. 
 Another non-canonical way in which Stx may act is 
through a delivery system in Stx-containing microvesicles 
from various types of cells. These microvesicles charged 
with Stx also have the intrinsic ability to induce thrombosis 
by activating coagulation factors, as they contain the acti-
vated complement components phosphatidylserine and tissue 
factor [55]. Free Stx in the bloodstream is almost undetect-
able, as it is either attached to blood cells or present in Stx-
containing microvesicles which have a cytotoxic effect 
equivalent to that of the free toxin. 
 Stx reaches the cerebral parenchyma by breaking the 
blood-brain barrier (BBB) [56]. However, alternative cere-
bral parenchyma routes of access should not be excluded, 
such as the blood-cerebrospinal fluid (CSF) barrier and cir-
cumventricular organs, i.e., structures located around the third 
and fourth ventricles characterized by a lack of the BBB. 
 Stx may also exert an important cytotoxic effect by in-
ducing a strong inflammatory status. This is achieved 
through the activation of leukocytes, endothelial cells and 
the alternative pathway of complement, with the consequent 
production of reactive oxygen species (ROS) and the release 
of cytokines/chemokines. This secondary effect may be 
heightened by LPS and it may contribute to the physiopa-
thology of the disease [57]. Furthermore, pro-inflammatory 
cytokines induced by LPS, such as TNF-α, promote the 
upregulation of Gb3, which increases cellular sensitivity to 
Stx [56, 58]. Clinical evidence supporting these events was 
found in patients with encephalopathy-derived STEC infec-
tions with elevated concentration of plasma TNF-α, a soluble 
form of types I and II TNF receptor, neopterin, IL-8 and IL-6 
[59, 60]. It has also been shown that LPS non-responder 
mice treated with Stx2, together with LPS, have mild sys-
temic symptoms with later isolated neurologic symptoms, in 
contrast with LPS responder mice, which develop a severe 
combination of gastrointestinal, neurologic and systemic 
symptoms. This indicates that the combination of Stx and 
LPS is a determinant contributor to the pathogenesis of the 
disease [61]. 
3. STX AND THE HUMAN CNS 
 The abnormal accumulation of metabolic products in 
circulation due to renal failure includes toxic compounds like 
creatinine and uric acid, among others, which may produce 
uremic encephalopathy leading to cognitive dysfunction, 
motor disorders and seizures [62]. During HUS, kidney 
damage correlates with an increase in these metabolites, al-
though up to 15% of the patients positively diagnosed with 
STEC develop encephalopathy before the onset of HUS. 
This event supports the hypothesis that the cerebral damage 
in STEC infections may be produced directly by Stx in the 
neural tissue and not by a mere accumulation of metabolic 
products due to renal failure [63]. 
 In humans, CNS symptoms of this disease are diverse, 
with patients suffering from blindness, hyperreflexia, deficits 
in orientation, attention or memory abilities, poor fine-motor 
coordination, seizures or irregular myoclonus and coma, 
among others [64-76]. Brain magnetic resonance images 
have also shown recurrent edema with hemorrhagic compo-
nents, which indicates the presence of inflammation and vas-
cular damage. These changes were observed in distinct brain 
areas such as basal ganglion, thalamus, midbrain, corpus 
callosum, cerebellum, white matter and brain stem [64-66, 
68-73]. Furthermore, CSF analyses have shown an elevated 
protein concentration in 10 to 30% of patients. This fact is 
consistent with BBB disruption, as protein concentration in 
normal CSF is low compared to serum [67, 77]. 
 In addition, post-mortem samples have shown edema and 
focal infarcts due to hypoxic/anoxic/ischemic events [77]. 
Focal microhemorrhages are often found together with hy-
poxic-ischemic changes throughout the brain. Although the 
pathophysiology of HUS involves small vessel occlusions, 
cerebral occlusive syndromes are not frequently reported. 
Very few histopathological findings have reported micro 
thrombosis in the CNS, which suggests the involvement of 
endothelial damage with no significant platelet or coagula-
tion activation [73, 78]. 
 In May 2011, an outbreak of STEC was reported in 
northern Germany, with a total of 53 associated deaths. Ac-
cording to the final report of the Robert-Koch-Institute [71], 
a total of 3842 patients were infected with STEC O104:H4, 
while 855 patients developed HUS and exhibited neurologi-
cal symptoms in the seventh day after the onset of diarrhea. 
Neurological symptoms in these cases included double vi-
sion, difficulties in finding words, hyperreflexia, deficits in 
orientation, attention or memory abilities and seizures, 
among others. Almost 29 % of those patients needed me-
chanical ventilation in the course of the disease due to severe 
alteration of consciousness. Furthermore, the severity of en-
cephalopathy is usually accompanied by increased pro-
inflammatory TNF-α and IL-1β cytokines, which suggests an 
important role of cytokines in the pathogenesis of the dis-
ease. Infection by STEC leads to the production of these 
cytokines not only in the intestine, but also in systemic circu-
lation and in the brain [70]. In addition, in 2019, the Center 
for Disease, Control and Prevention (CDC) reported five 
outbreaks of STEC infection triggered by the intake of the 
following contaminated foods: fresh express sunflower crisp 
chopped salad kits, romaine lettuce, ground bison, flour  
and ground beef (https://www.cdc.gov/ecoli/2019/o103-04-
19/index.html) 
4. PHARMACOLOGY 
 Although conservative therapy appears to be a well-
accepted treatment for HUS patients, no consensus therapy 
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Fig. (2). Stx cellular pathway, action and therapeutic strategies to block it. Black arrows show Stx cellular pathway and action: binding of 
Stx to Gb3, endocytosis process, the retrograde pathway to trans-Golgi network and endoplasmic reticulum. A1 subunit reaches cytosolic 
ribosomes, inhibits protein synthesis and leads to apoptosis. Red blunt arrows show specific Stx pathway and action blocked by each 
therapeutic approach. (A higher resolution / colour version of this figure is available in the electronic copy of the article). 
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Fig. (3). Therapeutic strategies to protect the CNS against Shiga toxin. Black arrows show the consequences of STEC infection and the 
direct effects of Stx in the body. Question mark on black arrows suggests a cellular effect of Stx not described yet. Green arrows show the cell 
release of deleterious factors in response to Stx. Red blunt arrows show specific Stx pathway and action blocked by each therapeutic approach 
or an inhibitory effect of these drugs on STEC bacteria in the gut mucosa. Blue arrow shows drugs that produce their neuropharmacological 
action without blocking any specific Stx pathway or action. Green cell: astrocyte in contact with a vessel; red cell: microglia; blue cell: 
oligodendrocyte; orange cell: neuron. BBB: blood-brain-barrier; PMN: polymorphonuclear. (A higher resolution / colour version of this fig-
ure is available in the electronic copy of the article). 
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Table 1. Brief description of the drugs analyzed in this review. 
Drug Class Drug Type of Study Effect Refs. 
Inhibited the interacion of StxA with TLR4. 
Polymyxin B In vitro (human neutrophils) 
Inhibition of neutrophils activation. 
Carnicelli et al., 2016 [76] 
Polymyxin E (Colistin) In vitro (E. coli O157:H7) Reduced in a dose-dependent manerthe release of Stx2 and LPS. Percivalle et al., 2016 [83] 
Fosfomycin Clinical study Protected patients against Stx Ikeda et al., 1999 [90] 
In vitro (E. coli O86:H-) Had a low MIC and inhibited Stx production 
In vitro (Human mononuclear 
cells) 
Inhibited the Stx1/Stx2-stimulated cytokine production 
In vivo (murine model) Decreased in Stx-induced proinflamatory citokynes production 
Antibiotics 
Azythromycin 
  Protected effect against Stx challenge 
Ohara et al., 2002 [92] 
Reduced rabbit mortality 
Betamethasone In vivo (rabbit model) 
Protected rabbit against brain edema 
Fujii et al., 2009 [102] 
Case report Reduced systemic proinflammatory cytokines Oki et al., 2008 [104] 
Case roport Patient recovered without any sequela Yoshimitsu et al., 2011 [105] 
Case report Improved the patient condition Shimizu et al., 2014 [57] 
Clinical study Patients recovered completely Takanashi et al., 2014 [103]  
Case report Patient condition improved gradually Ito et al., 2015 [56] 
Case report Improved the patient condition Yada et al., 2015 [106] 
Clinical study Increased the patients good outcome Kuroda et al., 2015 [107] 
Methylprednisolone 
Case report Patient recover without any sequela Hosaka et al., 2017 [91] 
increased the survival of mice challenged with a lethal doses of Stx2   
Protected neuronal populations present in different brain regions Pinto et al., 2013 [112] 
Reduced astrocyte/microglial reaction & damage to the myelin sheath Pinto et al., 2017 [53] 
Protected the BBB & restored the basal expression of VEGF Pinto et al., 2018 [113] 
Dexamethasone In vivo (murine model) 
Reversed changes in mice behavior   
Anti-
inflammatory 
Etanercept In vivo (rat model) Reduced the Stx2 uptake by neurons & its lethal effect Pinto et al., 2018 [113] 
In vitro (mixed glia mouse 
culture) 
Did not prevent oligodendrocyte damage 
Angiotensin 1-7 
In vivo (rat model) Prevented Stx2-induced damage in neurons and oligodendrocytes 
Goldstein et al., 2016 [118] 
In vitro (Human monocytic 
cells) 
Inhibited the production of TNF-α, IL-1β and IL-8 
Vasoactive drugs 
Anisodamine 
In vivo (murine model) Increased the survival of Stx1-treated mice 
Zhang et al., 2000 [135] 
Clinical study Improved the patient condition rapidly Lapeyraque et al., 2011 [147] 
Clinical study Produced a good neurological outcome Gitiaux et al., 2013 [145] 
Case report Produced an improvement of the patiant neurologic status Saini et al., 2015 [149] 
Clinical study Produced a good neurological outcome Pape et al., 2015 [65] 
Antibodies Eculizumab 
Review Produced a positive improvement in patient condition Mahat et al., 2019 [148] 
(Table 1) contd…. 
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Drug Class Drug Type of Study Effect Refs. 
In vivo (murine model) Protected mice challenged with a lethal charge of STEC and from Stx 
Yamagami et al., 2001 [160]; 
Kimura et al., 2002 [158] 
In vitro (ACHN cells) Protected cells against Stx Kimura et al., 2002 [158] 
In vivo (murine model) Prevented the lethal effects of Stx Santer et al., 2008 [161] 
In vivo (murine model) Protected mice challenged with Stx 
In vitro (Vero cells) Protected cells against Stx 
Mejias et al., 2016 [157] 
Antibodys anti-Stx 
Phase 1 safety and phar-
macokinetic study 
Were well tolerated by patients 
Dowling 2005 [162]; Bitzan 
2009 [163]; Lopez 2010 [164] 
Antibodies 
Stx vaccine In vivo (murine model) 
Protected mice challenge with a lehtal dose of Stx2 or lethal charge with 
EHEC 
Mejias et al., 2013 [166]; 
Mejias et al., 2014 [165] 
Polyphenols In vitro (Vero cells) Protected cells against Stx Quinones et al., 2009 [172] 
In vitro (Vero cells) Protected cells against Stx Vinh et al., 2019 [176] 
In vitro (HELA cells) Protected cells against Stx 
Dong et al., 2015 [174]; 
Zhang et al., 2017 [175] 
In vivo (mice) Protected mice challenged with Stx Dong et al., 2015 [177] 
Baicalin 
In vivo (mice) Protected mice challenged with a lethal charge of E. coli O157:H7 Zhang et al., 2017 [175] 
Polyphenols 
Catechins In vitro (E. coli O157:H7) inhibited bacteria growth and suppressed the release of Stx from STEC 
Sugita-Konishi et al., 1999 
[177] 
In vitro (Human HT29 
cells ) 
Protected cells against Stx 
Olano-Martin et al., 2003 
[189] 
prebiotics 
In vitro (Human HT29 
cells ) 
Inhibited E. coli O157:H7 adhesion to cells and reduced Stx cytotoxicity Di al., 2017 [190] 
In vitro (E.coli O104:H4 
and O157:H7) 
Inhibited STEC growth and Stx espresion Mohsin et al.,2015 [193] 
In vitro (E.coli O104:H4 
and O157:H7) 
Reduced STEC growth and inhibited Stx release Rund 2013 [194] 
Pharmabiotics 
probiotics 
In vitro (several STEC 
strains) 
Reduced STEC growth and inhibited Stx release Reissbrodt et al., 2009 [195] 
Stem cells Muse cells In vivo (mice model) 
Protected mice chalenged with STEC and prevented neuronal damage 
from Stx 
Ozuru 2019 [198] 
In vitro (THP1 and U937 
cells)  
Protected cells against Stx Proteasome 
inhibitor 
Bortezomib 
In vivo (mice) Protected mice challenged with Stx 
Hattori et al., 2015 [201] 
Inhibitor of Gb3 
synthesis 





Case report Improved in neurological and renal function Flam et al., 2016 [203] 
Lipids Lysophospholipids In vitro (HEp-2 cells) Inhibited the binding of Stx to Gb3 and its toxicity Aite et al., 2016 [205] 
In vitro (He La cells) Retro-1 and Retro-2 protected the cells against Stx Stechmann et al., 2010 [206] 
In vivo (murine model) Retro-2cycl protected mice chalanged with STEC O104:H4 Secher et al., 2015 [208] 




Retro-1, Retro-2 & 
Retro-2cycl 
In vivo (murine model) Retro-2 protected mice chalanged with STEC O104:H4 Gupta et al., 2017 [209] 
(Table 1) contd…. 
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Drug Class Drug Type of Study Effect Refs. 
In vitro (He La cells) Inhibited the trafficking and toxicity of Stx 
 Tamoxifen 
In vivo (mice) protected mice from a lethal dose of Stx 
Selyunin et al., 2019 [213] 
In vitro (E. coli O157:H7 & O104:H21) Reduced the bacterial growth  Subils et al., 2014 [215] 
Bismuth 
In vitro (E. coli O157:H7) Reduced the bacterial growth an production of Stx Pitz et al., 2015 [214] 
Zinc In vitro (T84 cells) 
Prevented the translocation of Stx into cel monolayers and 
inhibited SOS system expression 
Crane et al., 2014 [216] 
Metals 
Manganese In vitro (He La cells) Protected cells against Stx Tewari et al., 2014 [217] 
 
 
seems to be currently available to treat STEC-derived en-
cephalopathy. In the last few years, several drugs have been 
experimentally employed to establish the pathogenesis of, to 
prevent or to treat CNS injury by STEC, with strategies rely-
ing on drug capability to inhibit either toxin entry into the 
cerebral parenchyma or its deleterious action once inside the 
CNS. Therefore, the therapeutic strategies that we postulate 
and describe in this review and which have been or may be 
used are: 1) inhibition of Stx production and release by 
STEC, 2) inhibition of Stx bloodstream transport, 3) inhibi-
tion of Stx entry into the CNS parenchyma, 4) blockade of 
deleterious Stx action in neural cells and 5) inhibition of 
immune system activation and CNS inflammation (Figs 2 
and 3). Table 1 describes a quick description of the drugs 
analyzed in this review. 
4.1. Antibiotics used to Reduce STEC Encephalopathies 
4.1.1. Polymyxin 
 Antibiotic administration is not recommended in the pro-
dromal intestinal phase of human STEC infections, as it in-
duces the phage lysogenic cycle with the consequent in-
crease in expression and release of Stx2 [17]. However, 
strong evidence suggests that the antibiotic polymyxin B 
blocks the interaction of Stx with human neutrophils and 
impairs their capability to respond to Stx, inhibiting the re-
lease of chemokines and pro-inflammatory cytokines such as 
CXCL8, TNF-α and IL-1B [79]. This blockade is most likely 
to take place through the interaction of polymyxin B with the 
A chain of Stx, responsible for binding with human neutro-
phil TLR4 [50, 54, 79-84]). Polymyxin B appears to exert 
the same protective effect against LPS [85], inhibiting its 
interaction with TLR4 present in monocytes and platelets 
and preventing the activation of these cells and the upregula-
tion of Gb3 produced by pro-inflammatory cytokines, as 
discussed above. In addition to polymyxin B, in vitro studies 
have shown that polymyxin E (colistin) is also efficient in 
inhibiting bacterial growth and Stx production by E. coli 
O157:H7 [86]. 
 Polymyxin is a class of polypeptide antibiotics developed 
in the 1940s, which consists of amphipathic lipopeptide 
molecules derived from the fermentation products of bacteria 
Paenibacillus polymyxa. Both polymyxin B and colistin are 
bactericidal antibiotics whose mode of action remains con-
troversial [79, 86-89]. It was suggested that they may act as 
an amphipathic detergent producing pore-like aggregates, 
which culminates in bacterial death, as well as the inhibition 
of cytokine release and LPS neutralizing effects [88, 89]. As 
they do not cause damage in bacterial DNA, the bacterial 
SOS response (response to DNA damage which promotes 
the transcription of Stx genes carried by the bacteriophage 
genome) is not elicited, and Stx genes are therefore not ex-
pressed before cell death [79, 86]. 
 However, caution is necessary for the study of Stx inhibi-
tion by polymyxin B. As the antibiotic blocks the interaction 
between StxA and TLR4, it would be pointless to study it in 
a murine model, since murine PMN expresses Gb3 as well as 
TLR4 [82], in contrast with human PMN, which only ex-
presses TLR4 [90]. In these conditions, StxB will be prefer-
entially bound to Gb3 [82]. As a consequence, other animal 
models should be employed to establish the efficacy of po-
lymyxin B and its derivatives to block the Stx effect [79]. 
Two major adverse effects in polymyxin treatment are neph-
rotoxicity and neuromuscular joint blockade. These effects, 
however, could be bypassed through oral administration, as 
polymyxin is only slightly absorbed and mostly eliminated 
by the gastrointestinal tract [86]. In sum, more research is 
needed on polymyxin beneficial effects. 
4.1.2. Fosfomycin 
 Fosfomycin is a bactericidal broad-spectrum antibiotic 
first isolated in 1969 from cultures of Streptomyces spp. This 
antibiotic has a unique mechanism of action in which it re-
duces penicillin-binding proteins and inhibits the first step in 
peptidoglycan biosynthesis, leading to bacterial cell lysis and 
death. It reaches the bacterial cytoplasm using both the 
hexose monophosphate and the L-a-glycerophosphate trans-
port system [91]. 
 A study of 118 children with STEC infection between 
1997 and 2013 [92] determined that the use of fosfomycin 
within the first 5 days of STEC infection restricted the de-
velopment of HUS. Furthermore, another study of 292 chil-
dren with E. coli O157 infection [93] reported that fosfomy-
cin should be administered in a rather smaller time window, 
during the first 2 days of illness, in order to reduce the risk of 
HUS. However, a case report in 2017 [94] described the evo-
lution of a 20-year-old woman whose digestive symptoms 
improved after fosfomycin treatment four days from the be-
ginning of gastroenteritis with EHEC O26, who was then 
diagnosed with HUS a day after treatment. This patient be-
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gan supportive care treatment with improvements in symp-
toms but developed acute encephalopathy five days later. 
Subsequent treatment with 1g/day methylprednisolone pulse 
therapy (mPSL) for three days later proved to be beneficial, 
as neurologic symptoms, hemolytic anemia, low platelet 
count and renal dysfunction all improved. The patient was 
finally discharged without any sequelae 23 days later. 
4.1.3. Azithromycin 
 Azithromycin, a broad-spectrum macrolide antibiotic 
with bacteriostatic activity against many Gram-positive and 
Gram-negative bacteria, has also been reported as a possible 
therapeutic strategy to be employed due to its potential bene-
ficial effect in the prevention of HUS and/or encephalopathy 
derived from infection with STEC [95]. In contrast to newer 
fluoroquinolones [96, 97], azithromycin has been able to 
inhibit the in vitro growth of STEC strains without the pro-
duction of Stx. Another characteristic of this class of antibi-
otics is its immunomodulatory activities, such as the inhibi-
tion of neutrophil chemotaxis and oxidative burst and the 
release of pro-inflammatory cytokines from monocytes [98-
101]. Azithromycin can also inhibit the Stx-induced produc-
tion of inflammatory cytokines TNF-, IL-1 and IL-6 and 
prevent death in mice exposed to Stx or STEC [95]. 
4.2. Anti-inflammatory Drugs 
4.2.1. Corticosteroid 
 Given the importance of the pro-inflammatory response 
produced by Stx and LPS, several authors have reported the 
use of anti-inflammatory steroids in clinical cases and in 
animal models of encephalopathy produced by Stx. Clini-
cally, corticosteroid therapy has been used since the early 
1960s [102, 103], although controversial results in therapy 
success have also been reported [104]. 
4.2.1.1. Betamethasone 
 Betamethasone is a synthetic, long-acting corticosteroid 
with high potency glucocorticoid (25 times more potent than 
cortisol) but minimal mineralocorticoid activity. Betametha-
sone pulse therapy has been found to reduce the mortality 
rate and improve the survival period of Stx2-toxemic rabbits 
with doses 8 times higher than those used in humans [105]. 
4.2.1.2. Methylprednisolone 
 Still, currently in use, methylprednisolone therapy has 
been extensively reported to exert neuroprotective effects 
and reverse CNS damage without sequelae [59, 60, 94, 106-
110].  
4.2.1.3 Dexamethasone 
 As corticosteroid is used in animal models, dexametha-
sone has proven to be a good neuroprotective candidate and 
is one of the most common corticosteroids used in medicine. 
It has a biological response thirty times more potent than 
endogenous cortisol and, in contrast to the latter, has virtu-
ally no mineralocorticoid effects [111]. Many of the anti-
inflammatory effects of glucocorticoids are mediated by 
their inhibitory action on inflammatory cells, the generation 
of arachidonic acid-derived pro-inflammatory mediators and 
cytokine production [112]. Furthermore, dexamethasone 
blocks platelet aggregation [113] and increases the expres-
sion of occludin, a protein present in BBB endothelial tight 
junctions [111], which makes the BBB less permeable. 
 Dexamethasone has been shown to increase the survival 
of mice challenged with two lethal doses of Stx2 and, conse-
quently, to protect neuronal populations, reduce astro-
cyte/microglial reactivity, myelin sheath damage and BBB 
permeability, and restore endothelial VEGF basal expression 
[56, 105, 114-116]. Overall, treatment with dexamethasone 
results in improved motor behavior. 
4.2.2. Etanercept 
 This anti-inflammatory drug is a TNF-α inhibitor which 
blocks its interaction with cell surface TNF-α receptors. 
Etanercept is a dimeric fusion protein consisting of the ex-
tracellular ligand-binding portion of the human TNF-α re-
ceptor linked to the Fc portion of human IgG1 and is pro-
duced by recombinant DNA technology in a Chinese ham-
ster ovary mammalian cell expression system [117, 118]. 
Etanercept has a binding affinity to TNF-α, which is up to 
1000-fold higher than that of the natural TNF-α receptors 
[119]. Etanercept has been reported to protect animals 
against a lethal dose of Stx2 through a reduction in neuronal 
Stx2 uptake [116]. As etanercept promotes the clearance of 
TNF-α, it may be thought to prevent Gb3 neuronal up-
regulation induced by TNF-α and other pro-inflammatory 
cytokines [58, 116]. 
 However, the anti-inflammatory efficacy of etanercept is 
reduced in prolonged administration. Although the underly-
ing mechanisms have not been described yet, a possible ex-
planation lies in the development of anti-etanercept antibod-
ies. This effect may be prevented through combined treat-
ment with corticosteroids, as recommended in the case of 
psoriatic arthritis [120]. 
4.3. Vasoactive Drugs 
4.3.1. Angiotensin 1-7 
 A recent article reported that angiotensin 1-7 succeeded 
in preventing neural damage following the intra-cerebro-
ventricular treatment of Stx2 [121]. For many years since the 
development of the first oral inhibitor of the angiotensin-
converting enzyme (ACE), responsible for the conversion of 
angiotensin I to angiotensin II, the renin-angiotensin system 
(RAS) has been the primary therapeutic target for the treat-
ment of hypertension and related diseases. An alternative 
pathway for angiotensin metabolism and signaling is related 
to the action of the angiotensin-converting enzyme 2 
(ACE2), which transforms angiotensin II into angiotensin 1-
7 [122]. The latter exerts its effect through a unique G-
protein-coupled receptor known as MAS. The activation of 
MAS produces anti-inflammatory, antioxidant, vasodilatory 
and angiogenic effects, which have proven beneficial in 
many animal models of CNS damage by stroke [123-127] 
and inflammation-related disease models including arthritis, 
hypertensive kidney disease, atherosclerosis, asthma and 
acute respiratory distress syndrome [128-132]. In this model, 
Stx2 produced neurodegeneration, demyelination and astro-
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cyte damage, accompanied by edema, which angiotensin 1–7 
was able to prevent in neurons and oligodendrocytes, but 
partially only in astrocytes. On the other hand, angiotensin 1-
7 failed to prevent in vitro oligodendrocyte damage produced 
by Stx2, which suggests that its protective effects may be 
mediated by its neuronal receptor [133, 134], with a key role 
of cellular interaction. 
4.3.2. Anisodamine 
 Another vasoactive drug employed in Stx-producing dis-
ease models, anisodamine (6-[s]hydroxyhyoscyamine), is an 
atropine derivative from Scopaliatangutica [135]. This drug 
is a non-specific cholinergic antagonist with respect to M1 
and M2 receptors and appears to be less potent and toxic 
than atropine [136]. Anisodamine has vasodilating activity 
due to its relatively weak α1 adrenergic antagonism, and 
experimental evidence suggests antioxidant and superoxide 
scavenging activity as well [135]. Moreover, anisodamine 
presents antithrombotic activity, as it inhibits thromboxane 
synthesis [137]. Broad therapeutic uses have been proposed, 
including disorders related to the autonomic nervous system, 
migraine, gastric ulcers, gastrointestinal colic, acute glome-
rulonephritis, eclampsia, respiratory diseases, rheumatoid 
arthritis, snake bites and radiation damage, among others 
[135]. 
 In Stx1-producing disease models, anisodamine has been 
able to increase the survival of Stx1-treated mice, a benefi-
cial effect which may be due to the inhibition of proinflam-
matory cytokine TNF-α, IL-1β and IL-8 synthesis by human 
peripheral blood monocytes via a PGE2-dependent mecha-
nism. Furthermore, anisodamine may also produce a benefi-
cial effect by improving microvascular circulation [138]. 
4.4. Antibodies 
4.4.1. Eculizumab 
 Several authors have reported hypocomplementemia in 
approximately one-third of children with HUS [139-146]. 
This clinical sign is strongly associated with severe episodes 
of HUS-derived encephalopathy and with poor prognosis 
[140, 147]. It is not clear why Stx promotes the complement 
system activation only in a fraction of affected children; 
however, children with hypocomplementemia are known to 
be significantly younger than those with normal blood com-
plement levels [140]. 
 Circulating Stx directly activates the complement system 
and also binds and neutralizes factor H, a soluble comple-
ment regulator essential for controlling the alternative path-
way [148]. Therefore, treatment with a complement inhibitor 
may be beneficial to prevent STEC-derived encephalopathies 
and, consequently, death from this disease. 
 Accordingly, many reported cases of STEC-derived en-
cephalopathies describe the therapeutic use of the C5 com-
plement molecule inhibitor eculizumab [68, 140, 141, 148-
152]. Eculizumab is a humanized chimeric monoclonal anti-
body comprising a human constant region and a murine 
complementarity determining region grafted onto human 
framework light and heavy chain variable regions. It is de-
signed to bind one or two C5 molecules to inhibit their acti-
vation and thus block terminal complement activation [148, 
153, 154]. 
 Although the pathogenic mechanism in encephalopathy 
produced by Stx is not yet fully understood, evidence sug-
gests direct damage of neural cells by the toxin [155], indi-
rect cerebral damage by inflammation [56, 115, 116] and 
cerebral thrombotic microangiopathy [156]. Complement-
mediated neurological impairment in STEC infections has 
been described by many authors and early treatment with 
eculizumab has proven more efficient than plasmapheresis in 
improving neurological status [69]. In contrast, late eculizu-
mab treatment following unsuccessful treatment with plas-
mapheresis has shown no benefits [157]. 
4.4.2. Passive and Active Immune Therapy 
 A logical strategy to protect the CNS against the detri-
mental action of Stx is the employment of passive immune 
therapy with anti-Stx antibodies or active immune therapy to 
neutralize the toxin long before brain damage occurs. In this 
context, pre-clinical studies using chimeric murine-human 
monoclonal antibodies have been developed since the late 
1980s [158] and are, until now, the most effective treatment 
so far. In vitro and in vivo models [159-164] using mono-
clonal antibodies have demonstrated success in neutralizing 
the toxic and lethal effects of Stx, respectively. Recently, 
healthy adult volunteers have received treatment with anti-
Stx antibodies corresponding to phase 1 safety and pharma-
cokinetic trials [159, 165-167]. These studies showed that all 
these antibodies were well tolerated, which makes them 
good candidates to be employed in the next phase of clinical 
trials. 
 Neutralizing antibodies targeting StxB to prevent the 
binding of Stx to Gb3 constitute the theoretical basis of ac-
tive immunization against Stx. However, as it turns out to be 
StxB a poor immunogen researchers developed a vaccine with 
an engineered chimeric molecule consisting of StxB bound 
to Brucellaspp’s enzyme lumazine synthase [168, 169]. This 
new immunogen molecule has demonstrated a strong capac-
ity to induce long-lasting humoral immune response with a 
high neutralizing capacity for Stx2 in a murine model of sys-
temic delivery of Stx2 or even oral challenge of EHEC. This 
novel immunogen represents a promising candidate for vac-
cine or antibody development with preventive or therapeutic 
ends. Furthermore, female mice immunized before mating 
with the chimeric Brucella lumazine synthase-StxB devel-
oped a strong humoral response, while their offspring ac-
quired a very similar titer of the antibody through transpla-
cental and breastfeeding. Moreover, pups were totally pro-
tected against systemic injection of a lethal dose of Stx up to 
3 months postpartum and against EHEC infection at weaning 
[168]. 
4.5. Polyphenols 
 Polyphenols are phytochemicals primarily found in fruits, 
vegetables, cereals and beverages, which are generally in-
volved in defense against ultraviolet radiation or aggression 
by pathogens. More than 3 mg of polyphenols can be found 
per gram in fresh weight fruits like grapes, apples, pears, 
cherries and berries [170]. Epidemiological and associated 
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meta-analysis studies strongly suggest that long-term con-
sumption of diets rich in plant polyphenols offers protection 
against cancer, cardiovascular disease, diabetes, osteoporo-
sis, neurodegenerative diseases and infections [171-173]. 
The beneficial action of polyphenols may be due to the pres-
ence of an antioxidant phenolic group which can accept an 
electron to form a relatively stable phenosyl radical, thus 
increasing plasma antioxidant capacity [174]. Non-identified 
polyphenols from grape seed and pomace extracts were re-
ported as molecules with potential inhibitory power of the 
toxic effect of Stx, as observed in Vero cells [175]. 
4.5.1. Baicalin 
 Baicalin (5, 6-dihydroxy-7-O-glucuronide flavone) is a 
polyphenol from Scutellaria baicalens employed in tradi-
tional Chinese medicine for the treatment of lung and liver 
diseases, diarrhea, dysentery, high blood pressure, bleeding, 
insomnia and inflammation [176]. Baicalin presents various 
pharmacological properties, including anti-oxidative, anti-
viral, anti-inflammatory, anti-HIV and antineoplastic activity 
[177]. 
 Baicalin has been able to protect HeLa [178, 179] and 
Vero cells [180] against Stx2, either after pre-treatment with 
Baicalin or even upon pre-incubation with Stx2. In turn, 
mice were challenged either with a lethal dose of Stx [178] 
or a lethal charge of E. coli O157:H7 [179], both to be later 
treated with oral baicalin, showing 70% and 80% protection, 
respectively. Furthermore, baicalin reduced the systemic 
production of IL-1, IL-4, IL-6, TNF-α and INF-γ in both 
models. Although baicalin showed no effects on the produc-
tion or secretion of Stx, docking models revealed that the 
inhibitory activity of baicalin against Stx might be due to the 
formation of a binding structure inside the pocket of the 
StxB pentamers [180]. 
4.5.2. Catechins: Gallocatechin Gallate (GCg) and Epigal-
locatechin Gallate (EGCg) 
 Catechins are natural polyphenolic compounds found 
mainly in tea leaf (Camellia sinensis) and other vegetables 
[181-184]. These compounds have many valuable properties 
such as anti-bacterial, anti-viral, anti-oxidative and anti-
tumor activity [185-188]. 
 From six different catechin derivatives contained in green 
tea extracts, GCg and EGCg were found to inhibit bacterial 
growth. Furthermore, GCg and EGCg that suppressed the 
release of Stx from STEC failed to block the production of 
Stx, as they act by inhibiting the leakage of molecules from 
periplasm [181]. 
4.6. Pharmabiotics 
 Pharmabiotic is a general term denoting the therapeutic 
use of commensal microbiota, which includes the use of pre-
biotics and live probiotic microorganisms [189]. 
4.6.1. Prebiotics 
 Prebiotics are selectively fermented non-digestible food 
ingredients which induce specific changes in the composi-
tion and/or activity of the gastrointestinal microbiota and 
thus offer benefits to host health [190]. Typical prebiotics, 
such as fructo- or galacto-oligosaccharides or lactulose, are 
selectively fermented and thus increased by beneficial bacte-
ria in the colon [191]. Pectic oligosaccharides are derived 
from pectin, a polysaccharide found in high amounts in cit-
rus fruits, which presents a partially methylesterified ho-
mogalacturonan backbone [192]. When pectin is consumed, 
it reaches the colon and becomes fermented by microbiota, 
hence yielding oligosaccharides and smaller metabolites 
[192]. In vitro studies have demonstrated the protective role 
of pectin and pectic-oligosaccharides against Stx lethality in 
human colonic cell line HT29 [193]. Furthermore, pectic-
oligosaccharides showed anti-adhesive properties, inhibiting 
the binding of E. coli O157:H7 to human HT29 cells [194]. 
4.6.2. Probiotics 
 Probiotics are live non-pathogenic microorganisms (Sac-
charomyces boulardii yeast or lactic acid bacteria, such as 
Lactobacillus and Bifidobacterium species), which, when 
administered in adequate amounts, provide health benefits to 
the host [189, 195, 196]. Probiotics exert their beneficial 
effects through various mechanisms, including lowering in-
testinal pH, decreasing colonization and invasion by patho-
genic organisms and beneficially modifying the host immune 
response. Probiotics have been commonly targeted at ill-
nesses associated with the gastrointestinal tract, mainly due 
to their ability to restore gut microbiota [196]. 
 Escherichia coli Nissle 1917 (EcN) is a probiotic strain 
which has displayed an inhibitory effect on toxin growth and 
gene expression, Stx release and cytotoxicity in STEC sero-
types O104:H4 and O157:H7 [197]. Furthermore, adhesion 
of STEC strains to Caco-2 cells and mucin-producing LS 
174T cells has been significantly reduced upon co-culture 
with EcN [198]. On the other hand, routine quality control 
testing of STEC rendered Stx detection in only about 39% of 
all samples tested positive for STEC strains [199]. A particu-
lar E. coli strain isolated from stool samples of STEC-
infected Stx-negative patients, the non-probiotic E. coli 1307 
proved to possess probiotic like-properties similar to those of 
EcN, as it reduced bacterial growth and inhibited Stx release 
when co-cultured with STEC strains [199]. 
4.7. Stem Cells 
4.7.1. Multilineage-differentiating Stress-enduring (Muse) 
Cells 
 Muse cells are endogenous non-tumorigenic stem cells 
with the ability to sense, migrate to and populate the site of 
tissue damage, therefore replenishing it with new functional 
cells by spontaneous differentiation and inducing functional 
and structural repair. They are also stress-tolerant cells which 
perform anti-fibrotic, anti-inflammatory and anti-apoptotic 
functions. Due to their immunomodulatory effect, allograft 
and xenograft Muse cells may escape from host immu-
nologic attack and thus efficiently settle in the damaged site. 
Muse cells can be intravenously administrated to patients 
after collection and expansion from tissue sources [200]. 
Moreover, Muse cells have been applied to clinical trials for 
acute myocardial infarction, stroke and spinal cord injury by 
intravenous injection of donor-derived cells without HLA-
matching or immunosuppressant treatment [201]. Muse cells 
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have also shown a beneficial effect on STEC-associated 
acute encephalopathy, as they protected 100% of mice 
against lethal treatment with STEC O111. Immunohisto-
chemical analysis showed a decrease in astrocyte reactivity 
and caspase-3 inhibition, accompanied by a neuron-like 
morphology of the human Muse cells detected through an 
anti-Cox4 antibody in the mouse brain parenchyma. These 
findings suggest that Muse cells produced a beneficial effect 
by crossing the BBB. Furthermore, a single injection of as 
few as 5x104 Muse cells 48h after O111 infection proved to 
prevent neuronal damage by Stx [202]. 
 Among the compounds produced by Muse cells, the 
granulocyte-colony-stimulating factor (G-CSF) has been 
unequivocally identified as a neuroprotectant, as the suppres-
sion of G-CSF by iARN reduced the beneficial effects of 
these cells. G-CSF has also been observed to maintain aq-
uaporin type 4 integrity and induce vascular endothelial 
growth factor, which improved neurologic functions by re-
ducing brain edema, BBB permeability, neuronal death and 
apoptosis [203]. G-CSF also stimulated the proliferation of 
neuronal/glial progenitor cells, producing an improvement in 
neurocognitive function, and succeeded in repairing cerebral 
white matter damage by irradiation [204]. 
4.8. Proteasome Inhibitor 
 It has been reported that the clinically approved protea-
some inhibitor bortezomib manages to inhibit Stx1-induced 
apoptosis in vitro through the mitochondrial pathway of 
caspases 9-3. It was observed in vitro that the levels of apop-
tosis inhibitory proteins decreased due to proteasomal degra-
dation, followed by caspase activation and apoptosis pro-
gression. In this context, proteasome inhibitors succeeded in 
preventing the Stx-induced reduction in anti-apoptotic pro-
teins Apollon, XIAP, c-IAP1, FLIP and Mcl-1 and, conse-
quently, the progression of apoptosis. Furthermore, in vivo 
bortezomib administration prolonged the survival of mice 
intoxicated with Stx. Therefore, even if high 2mg/kg doses 
of bortezomib in the present study proved to be toxic and its 
potential clinical use should be handled with caution, inhibi-
tion of the proteasome may be beneficial in the treatment of 
patients affected by Stx intoxication [205]. 
4.9. Gb3 Synthesis Inhibitor 
 Another strategy to prevent the deleterious action of Stx 
is to reduce the expression of the Stx Gb3-receptor using C-9 
[(1R, 2R)-nonanoic acid [2-(2´, 3´-dihydro-benzo (1–4) di-
oxin-6´-yl)-2-hydroxy-1-pyrrolidin-1-ylmethyl-ethyl]-amide-
L-tartaric acid salt], a competitive inhibitor of the glucosyl-
ceramide synthase, responsible for rate-limiting the first step 
in the biosynthesis of Gb3 and globosides in general [206]. 
The use of this drug, administered 2 days before Stx2 sys-
temic delivery, managed to reduce the mortality rate in rats 
by 50%. However, the fact that C-9 does not cross the BBB 
may explain its failure in attaining total survival. Alterna-
tively, as C-9 inhibits the expression of the whole globoside 
series and knowledge currently available on Gb3 and other 
globosides biological functions is still limited, this drug may 
be thought to interfere with physiological functions, which 
calls for more preclinical studies with this drug in the treat-
ment of the systemic effects of STEC infection. 
4.10. Immunoglobulin G (IgG) Depletion 
 Another type of treatment employs IgG depletion by im-
munoadsorption, which has succeeded in rapidly improving 
neurological and renal functions. However, as the specificity 
of the antibody toward CNS antigens could not be identified, 
authors hypothesize that the effect of IgG depletion could be 
due to the elimination of autoantibodies or harmful immune 
complexes with Stx. Therefore, it has been postulated that 
late neurological involvement in STEC-HUS may be medi-
ated by immune factors [207]. 
4.11. Lysophospholipids 
 In vitro studies have shown that the conformation quality 
of the lipid bilayer of the plasma membrane could determine 
the binding of Stx to the Gb3 receptor [208]. In this regard, 
incubation of lysophospholipids such as lysophosphatidyli-
nositol, which has a large polar head with an extensive and 
saturated fatty acyl chain, has a conical structure that inhibits 
the binding of Stx or Stx2 to Gb3 and, hence, toxicity in 
HEp-2 cells. In contrast, this does not happen with lysophos-
pholipids having a small polar head and non-saturated 
shorter fatty acyl chains, which give a cylindrical structure. 
Therefore, lysophospholipids such as lysophosphatidylinosi-
tol change the physicochemical properties of the plasma 
membrane, which leads to alterations in the conformation 
and/or distribution of the Gb3 receptor [209]. 
4.12. Retrograde Transport Inhibitor 
4.12.1. Retro-1, Retro-2 & Retro-2cycl 
 Another strategy to neutralize the cytotoxic effect of Stx 
is inhibiting the retrograde transit of this toxin inside the 
cells. Three components have been found to specifically 
block the early endosome-to-trans Golgi network toxin 
transport step without affecting endogenous retrograde cargo 
proteins, other intracellular trafficking pathways, or, more 
generally, organelle integrity. It was observed that Retro-1 
and Retro-2 protected HeLa cells from the lethal effect of 
Stx [210, 211]. Moreover, Retro-2 and Retro-2cycl protected 
mice against a challenge with a lethal oral charge of STEC 
O104:H4 [212, 213]. 
4.12.2. Tamoxifen (TAM) 
 TAM is an antiestrogenic drug widely used for the treat-
ment of estrogen receptor-α-positive breast cancer [214]. 
TAM inhibits the trafficking and toxicity of Stx in HeLa 
cells, which lack estrogen receptors but are sensitive to Stx 
[215, 216]. This protective effect is independent of estrogen 
receptors but rather more related to TAM weak base proper-
ties, which increase endolysosomal pH. This property results 
from the chemical structure of TAM, characterized by a ter-
tiary amine group. As a result, TAM has been shown to pro-
tect mice from a lethal dose of Stx [217]. 
4.13. Divalent and Trivalent Metals 
 The antibacterial effects of certain trivalent/divalent met-
als have been demonstrated in recent years. Bismuth salts or 
colloidal bismuth hydroxide gel have been observed to reduce 
the bacterial growth of E. coli O157:H7 and E coli O104:H21 
in vitro within 48 hours, as evidenced by the degradation of 
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the cell wall, inhibition of plasma membrane function and 
impediment of protein and ATP synthesis [218, 219]. 
 It has been reported that zinc offered protection against 
STEC infection by reducing the expression of the SOS sys-
tem in the presence of hydrogen peroxide, xanthine oxidase 
or antibiotic ciprofloxacin in the gastrointestinal tract. Zinc 
also had protective effects on enterocytes, by restoring the 
impermeability of tight junctions, on the one hand, and pre-
venting the translocation of Stx into monolayers, on the other 
[220]. 
 Finally, manganese has been used to degrade cycling 
transmembrane protein GPP130, which Stx uses as an intra-
cellular traffic receptor. The role of manganese lies in its 
union with GPP130, which blocks toxin movement to the 
Golgi to be led to lysosomes, where it is degraded and puri-
fied from infected cells. Manganese treatment could then be 
accessible, given its low cost and availability [221]. 
CONCLUSION 
 At present, there is no consensus high-efficiency 
treatment for STEC infections and only supportive treatment 
is employed for STEC-infected patients. Once the patient is 
diagnosed, hospitalization and volume expansion therapy are 
required to monitor the progression of the disease and main-
tain the level of hydration, respectively [159]. In this review, 
we intended to provide a wide range of therapeutic strategies 
aimed, on the one hand, to eliminate the bacteria from the 
gut without producing and releasing Stx and, on the other 
hand, to block the action and the effect of Stx systemically 
and locally in the CNS. 
 An important question to be solved is when to start an 
effective treatment. There are only a few clinical studies re-
porting a therapeutic time window for effective pharmacol-
ogical treatment (fosfomycin within the first 2 to 5 days of 
STEC infection [92, 93]). Furthermore, the administration of 
Gb3 analogs orally provided to positively diagnosed diar-
rhea-HUS-patients has been tested as a treatment specifically 
aimed to neutralize the toxin at the intestinal level [222]. The 
study showed that patients who received Gb3 analogs had 
similar clinical evolution to those who received the placebo. 
This evidence suggests that the time window for therapeutic 
approaches aiming at preventing toxin release by bacteria 
and/or toxin arrival at the bloodstream is shorter than that 
required for drugs of systemic action. Therefore, fast diagno-
sis of STEC infection, as well as the establishment of early 
biomarkers of CNS damage, may be crucial to a rapid  
pharmacological approach. Early treatment by early diagnosis 
may lead to a better prognosis and a reduction in death or  
sequelae. 
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